Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease ; volume:12 ; number:1 ; day:13 ; month:12 ; year:2017 ; pages:1-12 ; date:12.2017
Orphanet journal of rare diseases ; 12, Heft 1 (13.12.2017), 1-12, 12.2017
- Urheber
-
Kanters, Tim A.
- Beteiligte Personen und Organisationen
-
van der Ploeg, Ans T.
Kruijshaar, Michelle E.
Rizopoulos, Dimitris
Redekop, W. Ken
Rutten-van Mӧlken, Maureen P. M. H.
Hakkaart-van Roijen, Leona
SpringerLink (Online service)
- DOI
-
10.1186/s13023-017-0731-0
- URN
-
urn:nbn:de:1111-201802111092
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kanters, Tim A.
- van der Ploeg, Ans T.
- Kruijshaar, Michelle E.
- Rizopoulos, Dimitris
- Redekop, W. Ken
- Rutten-van Mӧlken, Maureen P. M. H.
- Hakkaart-van Roijen, Leona
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
Improved Enzyme Replacement Therapy with Cipaglucosidase Alfa/Miglustat in Infantile Pompe Disease
STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa
Enzyme replacement therapy and fatigue in adults with Pompe disease
Long-Term Experience with Anaphylaxis and Desensitization to Alglucosidase Alfa in Pompe Disease
Impact of enzyme replacement therapy on survival in adults with Pompe disease
Enzyme replacement therapy (ERT) in pompe disease
Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry
Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy
Cipaglucosidase alfa (Morbus Pompe); Addendum zum Projekt A23-79 (Dossierbewertung)
Cipaglucosidase alfa (Morbus Pompe) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy
Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
Improved Enzyme Replacement Therapy with Cipaglucosidase Alfa/Miglustat in Infantile Pompe Disease
STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa
Enzyme replacement therapy and fatigue in adults with Pompe disease
Long-Term Experience with Anaphylaxis and Desensitization to Alglucosidase Alfa in Pompe Disease
Impact of enzyme replacement therapy on survival in adults with Pompe disease
Enzyme replacement therapy (ERT) in pompe disease
Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry
Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy
Cipaglucosidase alfa (Morbus Pompe); Addendum zum Projekt A23-79 (Dossierbewertung)
Cipaglucosidase alfa (Morbus Pompe) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy
Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
Improved Enzyme Replacement Therapy with Cipaglucosidase Alfa/Miglustat in Infantile Pompe Disease
STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa
Enzyme replacement therapy and fatigue in adults with Pompe disease
Long-Term Experience with Anaphylaxis and Desensitization to Alglucosidase Alfa in Pompe Disease
Impact of enzyme replacement therapy on survival in adults with Pompe disease
Enzyme replacement therapy (ERT) in pompe disease
Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry
Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy
Cipaglucosidase alfa (Morbus Pompe); Addendum zum Projekt A23-79 (Dossierbewertung)
Cipaglucosidase alfa (Morbus Pompe) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung